Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Completed · Phase 2

Conditions studied: Neuroblastoma

In brief

RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining different types of biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and sargramostim together with monoclonal antibody 3F8 works in treating patients with neuroblastoma that has not responded to previous treatment.

Key facts

Study ID

NCT00089258

Run by

Memorial Sloan Kettering Cancer Center

People needed

74

Starts

2004-07-01

Last updated by the study team

2013-01-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.